2021 Revenues ($USD) : $15,878,000,000
2021 R&D spend : $618,000,000
2021 Number of Employees : 37,037
Fiscal Year End : 12/31/2021
Leader : CEO Kåre Schultz

Israel-based Teva Pharmaceuticals had $15.9 billion in sales in 2021 but faced some headwinds related to COVID-19. Specializing in generics, Teva was founded in 1935 as Teva Middle East Pharmaceutical & Chemical Works Co. Ltd. in Jerusalem, Israel. Key products in its current portfolio include the Huntington's disease treatment Austedo (deutetrabenazine) and migraine treatment Ajovy (fremanezumab-vfrm). —BB